Canada · Delayed Price · Currency is CAD Gilead Sciences Statistics
Total Valuation
Gilead Sciences has a market cap or net worth of CAD 254.12 billion. The enterprise value is 284.43 billion.
| Market Cap | 254.12B |
| Enterprise Value | 284.43B |
Important Dates
The next estimated earnings date is Friday, November 6, 2026.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | Sep 15, 2026 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.39% |
| Shares Change (QoQ) | -0.88% |
| Owned by Insiders (%) | 0.09% |
| Owned by Institutions (%) | 91.13% |
| Float | 1.24B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 16.87 |
| PS Ratio | 5.91 |
| PB Ratio | 15.31 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 13.90 |
| P/OCF Ratio | 13.27 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.58, with an EV/FCF ratio of 15.55.
| EV / Earnings | n/a |
| EV / Sales | 6.59 |
| EV / EBITDA | 13.58 |
| EV / EBIT | 16.94 |
| EV / FCF | 15.55 |
Financial Position
The company has a current ratio of 1.27, with a Debt / Equity ratio of 2.23.
| Current Ratio | 1.27 |
| Quick Ratio | 0.90 |
| Debt / Equity | 2.23 |
| Debt / EBITDA | 1.78 |
| Debt / FCF | 2.03 |
| Interest Coverage | 11.86 |
Financial Efficiency
Return on equity (ROE) is -20.68% and return on invested capital (ROIC) is 34.37%.
| Return on Equity (ROE) | -20.68% |
| Return on Assets (ROA) | 14.09% |
| Return on Invested Capital (ROIC) | 34.37% |
| Return on Capital Employed (ROCE) | 30.88% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 2.54M |
| Profits Per Employee | -270,654 |
| Employee Count | 17,000 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 3.29 |
Taxes
In the past 12 months, Gilead Sciences has paid 1.82 billion in taxes.
| Income Tax | 1.82B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +24.87% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +24.87% |
| 50-Day Moving Average | 28.95 |
| 200-Day Moving Average | 27.69 |
| Relative Strength Index (RSI) | 43.01 |
| Average Volume (20 Days) | 9,532 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.94 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of CAD 43.25 billion and -4.60 billion in losses. Loss per share was -3.71.
| Revenue | 43.25B |
| Gross Profit | 34.43B |
| Operating Income | 16.82B |
| Pretax Income | -2.78B |
| Net Income | -4.60B |
| EBITDA | 20.73B |
| EBIT | 16.82B |
| Loss Per Share | -3.71 |
Balance Sheet
The company has 6.93 billion in cash and 37.27 billion in debt, with a net cash position of -30.34 billion.
| Cash & Cash Equivalents | 6.93B |
| Total Debt | 37.27B |
| Net Cash | -30.34B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 16.68B |
| Book Value Per Share | 13.54 |
| Working Capital | 4.15B |
Cash Flow
In the last 12 months, operating cash flow was 19.25 billion and capital expenditures -864.84 million, giving a free cash flow of 18.38 billion.
| Operating Cash Flow | 19.25B |
| Capital Expenditures | -864.84M |
| Depreciation & Amortization | 3.92B |
| Net Borrowing | 1.83B |
| Free Cash Flow | 18.38B |
| FCF Per Share | n/a |
Margins
Gross margin is 79.60%, with operating and profit margins of 38.88% and -10.64%.
| Gross Margin | 79.60% |
| Operating Margin | 38.88% |
| Pretax Margin | -6.42% |
| Profit Margin | -10.64% |
| EBITDA Margin | 47.94% |
| EBIT Margin | 38.88% |
| FCF Margin | 42.44% |
Dividends & Yields
This stock pays an annual dividend of 0.66, which amounts to a dividend yield of 2.30%.
| Dividend Per Share | 0.66 |
| Dividend Yield | 2.30% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.39% |
| Shareholder Yield | 3.67% |
| Earnings Yield | -1.80% |
| FCF Yield | 7.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gilead Sciences has an Altman Z-Score of 4.05 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.05 |
| Piotroski F-Score | 5 |